Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study.
2/5 보강
TL;DR
Biliary stent combined with iodine-125 intraluminal brachytherapy significantly prolonged SPT compared to stent-alone in patients with advanced pancreatic cancer complicated by obstructive jaundice, although it did not significantly improve survival outcomes.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
262 patients with advanced pancreatic cancer complicated by obstructive jaundice who had underwent metallic biliary stent implantation.
I · Intervention 중재 / 시술
metallic biliary stent implantation
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Biliary stent combined with iodine-125 intraluminal brachytherapy significantly prolonged SPT compared to stent-alone in patients with advanced pancreatic cancer complicated by obstructive jaundice, although it did not significantly improve survival outcomes. Higher ECOG performance score and higher CA19-9 level after jaundice reduce were associated with poor prognosis.
OpenAlex 토픽 ·
Pancreatic and Hepatic Oncology Research
Gallbladder and Bile Duct Disorders
Cholangiocarcinoma and Gallbladder Cancer Studies
Biliary stent combined with iodine-125 intraluminal brachytherapy significantly prolonged SPT compared to stent-alone in patients with advanced pancreatic cancer complicated by obstructive jaundice, a
- p-value P < 0.001
- p-value P = 0.002
- 95% CI 7.10-8.16
APA
Huiyi Sun, Yirou Zhou, et al. (2026). Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study.. Academic radiology, 33(4), 1355-1367. https://doi.org/10.1016/j.acra.2026.01.047
MLA
Huiyi Sun, et al.. "Iodine-125 Brachytherapy Combined with Biliary Stenting in Advanced Pancreatic Cancer: A Clinical Application Study.." Academic radiology, vol. 33, no. 4, 2026, pp. 1355-1367.
PMID
41720727 ↗
Abstract 한글 요약
[RATIONALE AND OBJECTIVES] This study aims to investigate the impact of iodine-125 intraluminal brachytherapy on stent patency time (SPT) and overall survival (OS) in patients with advanced pancreatic cancer complicated by obstructive jaundice, which may provide evidence for optimizing multimodal interventional strategies for patients with pancreatic cancer.
[METHODS] This retrospective study enrolled 262 patients with advanced pancreatic cancer complicated by obstructive jaundice who had underwent metallic biliary stent implantation. Patients were stratified into the I group and the control group. A 1:1 propensity score matching (PSM) was performed using a caliper width of 0.2 standard deviations of the propensity score.
[RESULTS] After 1 month of biliary stent implantation, significant reductions of serum bilirubin, transaminases, and CA19-9 levels compared to predrainage were observed in this study. A median SPT of 7.63 months (95% CI 7.10-8.16), a stent restenosis rate of 36.2%, and a median OS of 9.40 months (95% CI 9.11-9.69) was demonstrated in the entire cohort demonstrated. After 1:1 PSM (62 patients per group), the I group showed a significantly longer median SPT (9.44 months vs. 6.21 months, P < 0.001) and lower stent restenosis rate (17.7% vs. 43.5%, P = 0.002) compared to the control group. However, no significant OS difference was observed between groups (10.59 months vs. 9.07 months, P = 0.248). Cox analysis suggested that intratumoral brachytherapy (HR 0.382, P < 0.001) was an independent protective factor for SPT; post-stent Eastern Cooperative Oncology Group (ECOG) 2 score (HR 1.572, P = 0.019) was an independent risk factor for SPT. The independent risk factors for OS included post-stent ECOG 2 score (HR 1.469, P = 0.042) and post-stent CA19-9≥500 ku/L (HR 1.322, P = 0.046).
[CONCLUSION] Biliary stent combined with iodine-125 intraluminal brachytherapy significantly prolonged SPT compared to stent-alone in patients with advanced pancreatic cancer complicated by obstructive jaundice, although it did not significantly improve survival outcomes. Higher ECOG performance score and higher CA19-9 level after jaundice reduce were associated with poor prognosis.
[METHODS] This retrospective study enrolled 262 patients with advanced pancreatic cancer complicated by obstructive jaundice who had underwent metallic biliary stent implantation. Patients were stratified into the I group and the control group. A 1:1 propensity score matching (PSM) was performed using a caliper width of 0.2 standard deviations of the propensity score.
[RESULTS] After 1 month of biliary stent implantation, significant reductions of serum bilirubin, transaminases, and CA19-9 levels compared to predrainage were observed in this study. A median SPT of 7.63 months (95% CI 7.10-8.16), a stent restenosis rate of 36.2%, and a median OS of 9.40 months (95% CI 9.11-9.69) was demonstrated in the entire cohort demonstrated. After 1:1 PSM (62 patients per group), the I group showed a significantly longer median SPT (9.44 months vs. 6.21 months, P < 0.001) and lower stent restenosis rate (17.7% vs. 43.5%, P = 0.002) compared to the control group. However, no significant OS difference was observed between groups (10.59 months vs. 9.07 months, P = 0.248). Cox analysis suggested that intratumoral brachytherapy (HR 0.382, P < 0.001) was an independent protective factor for SPT; post-stent Eastern Cooperative Oncology Group (ECOG) 2 score (HR 1.572, P = 0.019) was an independent risk factor for SPT. The independent risk factors for OS included post-stent ECOG 2 score (HR 1.469, P = 0.042) and post-stent CA19-9≥500 ku/L (HR 1.322, P = 0.046).
[CONCLUSION] Biliary stent combined with iodine-125 intraluminal brachytherapy significantly prolonged SPT compared to stent-alone in patients with advanced pancreatic cancer complicated by obstructive jaundice, although it did not significantly improve survival outcomes. Higher ECOG performance score and higher CA19-9 level after jaundice reduce were associated with poor prognosis.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Iodine Radioisotopes
- Male
- Pancreatic Neoplasms
- Brachytherapy
- Female
- Stents
- Aged
- Middle Aged
- Treatment Outcome
- Retrospective Studies
- Survival Rate
- Jaundice
- Obstructive
- Combined Modality Therapy
- 80 and over
- Biliary stent
- Iodine-125 intraluminal brachytherapy Advanced pancreatic Cancer
- Obstructive jaundice
같은 제1저자의 인용 많은 논문 (5)
- Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology.
- Identification of N-tert-butyloxycarbonyl protected amino acids as novel hydrophobic tags to induce targeted protein degradation.
- Development of an SI-traceable magnetic solid-phase extraction coupled with isotope dilution LC-MS/MS method for accurate quantification of alpha-fetoprotein in human serum.
- Pulmonary origin and risk assessment of cancer-associated thrombosis.
- Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.